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Abstract 
Purpose: To investigate the anti-hyperuricemic effect of Dioscorea tokoro Makino extract (DTME) in 
potassium oxonate-induced hyperuricemic mice. 
Method: The effect of DTME was investigated in the hyperuricemic mice induced by potassium 
oxonate. DTME. The extract was administered to the mice daily at doses of 220, 440 and 880 mg/kg for 
10 days; allopurinol (5 mg/kg) was given as positive control. Serum and urine levels of uric acid and 
creatinine were determined by colorimetric method. Simultaneously, protein levels of urate transporter 1 
(URAT1) and organic anion transporter 1 (OAT1) in the rat kidney were analyzed by Western blotting.  
Results: Compared with control, a high dose of DTME inhibited xanthine oxidase (XOD) activity in both 
serum (18.12 ± 1.33 U/L) and in liver (70.15 ± 5.20 U/g protein) (p < 0.05); decreased levels of serum 
uric acid (2.04 ± 0.64 mg/L) (p < 0.05), serum creatinine (0.35 ± 0.18 µmol/L) and blood urea nitrogen 
(BUN) (8.83 ± 0.71 mmol/L) (p < 0.05). Furthermore, the extract increased levels of urine uric acid 
(38.34 ± 8.23 mg/L), urine creatinine (34.38 ± 1.98 mmol/L), down regulated of URAT1 and up regulated 
of OAT1 protein expressions (p < 0.05) in the renal tissue of hyperuricemic mice.  
Conclusion: DTME improves renal dysfunction in rats by regulating renal urate transporters in 
hyperuricemic rats. This may find therapeutic application in antihypertensive therapy.  
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Hyperuricemia is one of the most common and 
extensive metabolic diseases in populations, 
characterized by high uric acid level in the blood, 
causing deposition of urate crystals in the joints 
and kidneys, and is well known as important risk 
factor for gouty arthritis, uric acid nephrolithiasis, 
cardiovascular and renal disease, especially 
hypertension [1,2]. Despite advances in the use 
of anti-hyperuricemic agents for the treatment of 
hyperuricaemia and gout, allopurinol as a 
frequently used xanthine oxidase (XOD) inhibitor 
could induce severe hypersensitivity (such as a 
mild exanthema) and agranulocytosis, and 
aggravate renal toxicity by impairing pyrimidine 
metabolism [3,4]. Therefore, it is necessary to 
study available anti-hyperuricemic agents, 
especially herbal medicine [5]. 
 
Dioscorea tokoro Makino is widely used as a 
traditional Chinese herb for its efficiencyin 
treating hyperuricemia, gout and inflammatory 
arthritis in China [6], but its actual mechanisms in 
the hypouricemic process remains unclear. This 
study is to investigate therapeutic effects of 
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DTME on XOD activity and urate excretion in 




Plant material and extraction 
 
Samples of Dioscorea tokoro Makino were 
collected from Bozhou City, Anhui Province in 
China in May 2015. Taxonomic identification of 
the plant was performed by Professor HeHuang 
of Zhejiang University in China. A voucher 
specimen (no. DTME 20150517) was deposited 
in the Herbarium of College of Pharmacy, 
Zhejiang University, China for future reference. 
 
A whole plant of Dioscorea tokoro Makino was 
dried in an oven at 100 oC for 12 h. The aqueous 
extract of DTM was obtained by steeping the 
dried Dioscorea tokoro Makino in water at 60 oC 
three times, each for 1 h before first drying in an 
oven and then freeze-drying the last extract thus 
obtained. One gram powder was obtained from 
about 1.5 g dried sample, a yield of 66.7 %. 
 
Animals and experimental procedures 
 
Male ICR mice, weighing 18 - 22 g, were 
purchased from Animal Experimental Center, 
Zhejiang University, China. The rat experiment 
was approved by the Animal Care and Use 
Committee of Zhejiang University (approval ref 
no. 20121012) and was carried out in compliance 
with Directive 2010/63/EU on the handling of 
animals used for scientific purposes [7]. 
 
The uricase inhibitor potassium oxonate was 
used to induce hyperuricemia in mice according 
to previous reports [8]. Sixty mice were divided 
into six groups: normal group, model group, 
model plus allopurinol group, model plus high 
dose, plus middle dose and plus low dose of 
DTME groups. Each group had 10 mice.  
 
Model rats were treated with 250 mg/kg oxonate. 
Allopurinol group rats were treated with 
allopurinol (5 mg/kg); high dose, middle dose and 
low dose of DTME group rats were treated with 
880, 440 and 220 mg/kg DTME, respectively. 
Normal and control group rats were treated with 
water (10 ml/kg). 
 
Except the normal mice, other rats were all orally 
administered 250 mg/kg oxonate once daily for 7 
consecutive days to induce hyperuricemia. The 
drugs (allopurinol and DTME) were dispersed in 
water and were orally administered once daily 
from day 1 to day 10, while the normal mice was 




After 10 days of treatment, diets were removed 
from the cages 12 h before the animals were 
sacrificed by cervical vertebrae. Blood samples 
were collected by eyeball removal and 
centrifuged at 3500 × g for 20 min to obtain 
serum. The levels of XOD activities in serum and 
liver, serum and urinary levels of uric acid (UA), 
creatinine (Cr) and blood urea nitrogen (BUN) 
were determined by colorimetric method using 
commercially available kits (Shenzhen 
XinBoSheng Biological Technology Co. Ltd, 
China) according to the manufacturers’ 
instructions. 
 
Western blotting in kidney tissues 
 
Kidney samples were homogenized and lysed in 
SDS-PAGE sample buffer, centrifuged and the 
supernatant recovered. Samples were run on 10 
% SDS polyacrylamide gels, electroblotted onto 
nitrocellulose membranes. Immunoblotting was 
assayed using anti-URAT1, anti-OAT1 antibodies 
(Santa Cruz Biotech, USA). Detection was done 
using an enhanced chemiluminescence detection 
kit (Wuhan Boster Biological technology Ltd., 
Hunan, China). The band density were quantified 
using Lab works (GelPro 4.0, Media Cybernetics, 





All data were analyzed using SPSS 16.0 (SPSS 
Inc, Illinois, Chicago, USA) and are expressed as 
mean ± standard error of mean (SEM). The 
analysis was carried out by one-way analysis of 
variance (ANOVA) followed by Dunnett’s t-test. P 




Effect of DTME on serum and urinary levels 
of uric acid and creatinine, and blood urea 
nitrogen (BUN) 
 
As shown in the Table 1, after orally 
administration with potassium oxonate, the level 
of serum uric acid (SUA) in model group rats were 
significantly higher than those in normal group (p 
< 0.05), which indicated that the model was 
successful for inducing hyperuricemia in rats. 
Over a period of 10 days of treatment, compared 
with model group, the levels of SUA were 
suppressed significantly (p < 0.05) by DTME 
treatment at the dose of 220 - 880 mg/kg, while 
the levels of urinary uric acid (UUA) were 
increased significantly (p < 0.05). High dose of  
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Table 1: Effect of DTME on serum and urinary levels of UA and Cr, and BUN in hyperuricemic mice (n = 10) 
 











Normal - 1.42±0.18* 35.25±5.73* 0.29±0.11* 41.56±3.42* 7.58±0.85* 
Model - 6.13±0.76 12.68±4.79 0.95±0.38 17.33±4.68 16.43±1.13 
Allopurinol 5 1.85±0.37* 19.26±5.28 0.34±0.22* 24.26±3.32* 9.37±1.14* 
DTME-L 220 3.73±1.14* 19.79±6.21 0.56±0.21* 18.13±2.79 13.38±0.68* 
DTME-M 440 2.85±0.91* 28.65±7.55* 0.45±0.21* 26.72±3.02* 11.37±0.74* 
DTME-H 880 2.04±0.64* 38.34±8.23* 0.35±0.18* 34.38±1.98* 8.83±0.71* 
Data were expressed as mean ± SEM; p < 0.05 compared with model group. DTME-L: low dose of DTME, 
DTME-M: middle dose of DTME, DTME-H: high dose of DTME 
 
Table 2: Effect of DTME on XOD activities in the serum and liver of hyperuricemic mice (n = 10) 
 





Normal - 16.27±1.15* 65.34±3.68* 
Model - 26.58±1.46 84.53±4.56 
Allopurinol 5 18.43±1.24* 37.38±4.59* 
DTME-L 880 23.83±1.36 79.63±5.27 
DTME-M 440 22.65±1.42 76.14±5.34 
DTME-H 220 18.12±1.33* 70.15±5.20* 
Data are expressed as mean ± SEM; p < 0.05 compared with model group. DTME-L: low dose of DTME, DTME-
M: middle dose of DTME, DTME-H: high dose of DTME 
 
DTME also had significant effects on serum and 
hepatic XOD activities in hyperuricemic mice as 
showed in Table 2. Allopurinol at dose of 5 mg/kg 
significantly suppressed hepatic XOD activity of 
hyperuricemic mice (p < 0.01). Compared with 
the normal group, the levels of BUN and serum 
creatinine (SCr) were suppressed significantly 
(both p < 0.05) by DTME treatments at a dose of 
220 – 880 mg/kg, and conversely, the degree of 
promotion of urinary creatinine (UCr) levels 
induced by DTME at the treated doses was 
approximately 3 times more than that of 
allopurinol at a dose of 5 mg/kg and 
approximately 4 times more than that of the 
model group. Although both SUA and UUA levels 
in DTME-treated mice were higher than those in 
allopurinol-treated mice, DTME dose-
dependently enhances the UA excretion. 
 
Effect of DTME on organic anion transporter 
1 (OAT1) and urate transporter 1 (URAT1)  
 
As shown in Fig. 1, DTME dose-dependently 
decreased protein expressions of URAT1 and 
enhance OAT1 expressions in renal tissue of 
hyperuricemia mice. Compared with model 
group, protein expressions of URAT1 were 
significantly decreased in DTME-treated mice 
while the levels of OAT1 expression were 




Hyperuricemia is a major risk factor for gout and 
chronic nephritis in clinical practice. Recently, the 
therapeutic agents for lowering serum uric acid 
are limited because of their undesirable adverse 
effects. Potassium oxonate is usually used to 
prepare a rodent model of hyperuricemia by 
inhibiting uricase [8]. 
 
Some studies also demonstrated that traditional 
Chinese medicine could down-regulate hepatic 
XOD and enhance renal urate excretion in 
hyperuricemic mice [9]. However, in the previous 
reports [10], inhibitory effect of Simiao pill on 
XOD was lower than that of allopurinol. 
Therefore, to reverse the complicated pathologic 
state of hyperuricemia in the early phase, DTME 
was employed to enhance renal urate excretion. 
Compared with model group, the levels of serum 
uric acid were suppressed significantly by DTME 
treatment at the dose of 220 - 880 mg/kg, while 
the levels of urinary uric acid were increased 
significantly (p < 0.05). High dose of DTME also 
had significant effects on serum and hepatic 
XOD activities in hyperuricemic mice. 
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Figure 1: Protein expression of OAT1 and URAT1 in renal tissues by Western blot analysis. Representative 
immunoblot results. Densitometric analysis of blots for OAT1 and URAT1 protein. Values are mean ± SEM of 8 
animals. Asterisks denote significance levels; *p < 0.05, compared with model group 
 
Increasing clinical reports have shown that 
hyperuricemia is associated with not only gout, 
but also chronic nephritis and renal dysfunction 
[11]. BUN and SCr levels are useful indicators of 
renal function.  
 
Renal damage are accompanied by an increase 
in BUN and SCr indicating reduced urea and 
creatinine clearance [12]. Compared with the 
normal group, the levels of BUN and SCr were 
suppressed significantly (both p < 0.05) by 
DTME treatments at dose of 220 – 880 mg/kg, 
and conversely, the UCr levels induced by DTME 
at the treated doses was approximately 3 times 
more than that of allopurinol. 
 
The major regulator of SUA is renal excretion of 
uric acid. This renal exchange is mediated by 
specialized molecules expressed in renal 
proximal tubule cells, in which Urate transporter 
1 (URAT1) and organic anion transporter 1 
(OAT1) have been considered to play an 
important role in UA handling [13]. URAT1 is an 
important determinant of urate reabsorption. It is 
also a drug target which is inhibited by uricosuric 
drugs, such as benzbromarone, probenecid and 
losartan [14]. OAT1 mediate the active uptake of 
organic anions and controls the final exit into the 
urine via ATP-powered transporters and bi-
directional exchangers [15]. To evaluate the 
mechanism of DTME on the increase of UA 
clearance, effects of DTME on the URAT1 and 
OAT1 activation were examined. DTME dose-
dependently prevent protein expressions of 
URAT1 and enhance OAT1 expressions in renal 
tissue of hyperuricemia mice (both p < 0.05). 
These results are in accordance with the 
uricosuric effects of DTME on promotion of the 
UA excretion mentioned above and it also 
suggest that DTME inhibit oxonate-induced 
accumulation of SUA and reduction of urine 





DTME has a potent uricosuric effect by 
regulating renal urate transporters URAT1 and 
OAT1 in hyperuricemic mice. It should be 
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